Anbio Biotechnology Class A Ordinary Shares
NASDAQ: NNNN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
Updated 2026-04-29
Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for NNNN.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
NNNN historical valuation range
Where current P/E sits in NNNN's own 5Y range.
NNNN intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
NNNN valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 182.87x
P/S Ratio — History
Current: 139.23x
Is NNNN overvalued in 2026?
Anbio Biotechnology Class A Ordinary Shares (NNNN) currently trades at $27.43 per share with a market capitalization of $1,203,936,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 52/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 182.9x, above its 5-year median of 182.3x.
Looking at its own history, NNNN is currently trading more expensive than 71% of the last 5Y on P/E. This places it in the 71th percentile of its historical range, a reasonable but unremarkable position.
A standard DCF model does not produce reliable output for NNNN under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: NNNN trades at a fair valuation on our framework, with a Smart Value Score of 52/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is NNNN overvalued in 2026?
Based on a Smart Value Score of 52/100, NNNN is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is NNNN's fair value?
Standard DCF is unreliable for NNNN due to its current profitability profile. Revenue-based approaches such as EV/Sales or historical P/S percentile are more informative for this stock.
What P/E ratio does NNNN trade at?
NNNN trades at a P/E of 182.9x on trailing twelve-month earnings, compared to its 5-year median of 182.3x.
Is NNNN a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 52/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does NNNN's valuation compare to its history?
On P/E, NNNN currently sits in the 71th percentile of its own 5Y range. That is above its long-run median relative to where it has traded over the period.
What is NNNN's Smart Value Score?
NNNN's Smart Value Score is 52/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.